Tashkent hosted a satellite symposium “New Possibilities of IHD Therapy” organized by “Les Laboratoires SERVIER” Pharmaceutical Company – key partner of the congress – within the frameworks of the VII Eurasian Congress of Cardiology. Medical Express Journal was an information partner of the congress and symposium.
Preventive and Emergency Cardiology Chair Professor, Department for Postgraduate Continuous Education (DPCE), I.A. Sechenov Moscow Medical Academy (Sechenov MMA), Head of Laboratory for Functional Testing Methodology and Prudent Pharmacotherapy of Cardiovascular Diseases, Sechenov MMA and Municipal Clinical Hospital No. 59, Professor Maria G. Glezer, Doctor of Medical Science.
Professor Maria G. Glezer presented evidence-based information about a ischemic heart disease (coronary artery disease) case management strategy, prevention of complications, improvements of outcomes, elimination or mitigation of angina pectoris and myocardial ischemia as well as improvements in patients’ quality of life. Discussed issues concerned pharmacological therapy for improvement of treatment outcomes and necessary interventions to achieve blood pressure normalization. An ODA National Multicenter Observation Program to assess the efficacy and therapeutic response to daily practical use of Preductal OD 80 mg for treatment of stable angina pectoris was presented. Therapy aimed at correction of changes in energy metabolism, which is essential in case of ischemia, was described because it prevents initial stages of myocardial cell damage.
Junior Research Associate, Laboratory of IHD and Atherosclerosis, Republican Specialized Scientific and Practical Medical Center of Cardiology, Winner of 2016 Contest of Young Scholars. Nizamov, U. I. (Tashkent, Uzbekistan).
The presentation focused on ischemic heart disease (coronary artery disease) with emphasis anti-ischemic therapy using the example from a specific case. The presenter introduced a strategy for management of these cases. The speaker stressed the importance of reviewing a combination of anti-ischemic medications, which influence the treatment outcome in such patients and assessing the risk stratification for conducting revasculation.